Pharmaceutical company expects deal to further augment capabilities.
Shionogi, a Japanese pharmaceutical organization, has announced a definitive agreement to acquire Qpex Biopharma, Inc., a clinical stage pharma company with a background in antimicrobial research and development. According to Shionogi, the purchase will provide access to an investigational ß-lactamase inhibitor, providing critically needed antimicrobials, and enhancing R&D capabilities.
As part of the deal, Shionogi is expected to make upfront payments of $100 million to Qpex equity holders upon completion of the transaction, with a further $40 million becoming available upon the achievement of certain regulatory and development milestones.
“We are pleased to welcome Qpex into the Shionogi family. Bacterial resistance to antibiotics remains one of the biggest threats to global health, and Qpex’s pipeline, including xeruborbactam, and its capabilities will accelerate our efforts to develop new antibiotic treatments to address antimicrobial resistance,” said Isao Teshirogi, PhD, CEO, Shionogi. “Following the close of the acquisition, Qpex will become part of Shionogi, and we will work together to comprehensively address the needs of patients and healthcare professionals and to protect society from current and emerging life-threatening bacterial infections.”
Reference: Shionogi Further Extends Infectious Disease Innovation Platform with Planned Acquisition of Qpex Biopharma, Inc. Shionogi. June 25, 2023. Accessed June 28, 2023. https://www.shionogi.com/us/en/news/2023/06/shionogi-further-extends-infectious-disease-innovation-platform-with-planned-acquisition-of-qpex-biopharma-inc.html